Defibtech

Defibtech

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $35M

Overview

Defibtech is a privately held medical device manufacturer with a core mission to enhance survival from sudden cardiac arrest through innovative, accessible technology. The company operates in two primary segments: public-access AEDs for bystander use and professional-grade ACC devices for emergency personnel. With a long-standing presence since 1999, Defibtech has established itself as a key player in the cardiovascular resuscitation equipment market, leveraging a direct and distributor-based sales model. The company's strategy centers on product reliability, ease of use, and serving both the public safety and professional EMS markets.

Cardiovascular

Technology Platform

Platform for automated external defibrillation (AED) and automated mechanical chest compression (ACC) devices, focused on user-friendly design and reliability for both public and professional use.

Funding History

2
Total raised:$35M
Debt$15M
Series A$20M

Opportunities

Growth is driven by expanding public-access defibrillation legislation worldwide and increasing adoption of mechanical CPR devices by EMS and hospitals seeking to improve resuscitation quality.
International market expansion and the recurring revenue from consumables (pads, batteries) provide stable, long-term opportunities.

Risk Factors

Intense competition from larger, well-capitalized medical device companies poses pricing and market share risks.
The company is also exposed to significant product liability and regulatory hurdles, and its growth is partially dependent on public funding for AED programs.

Competitive Landscape

Defibtech competes in the AED market against giants like Philips (HeartStart), ZOLL (AED Plus), and Stryker (LIFEPAK). In the mechanical CPR segment, competitors include ZOLL (AutoPulse) and Physio-Control (LUCAS). The landscape is characterized by strong brand loyalty, continuous incremental innovation, and pressure on pricing.